

somatropin (Genotropin™) injection

Pfizer Limited

(No.240/06)

Product Update

10 February 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

somatropin (Genotropin™) injection is accepted for restricted use within NHS Scotland for the treatment of growth disturbance (current height Standard Deviation Score (SDS) <-2.5 and parental adjusted height SDS <-1) in short children born small for gestational age (SGA), with a birth weight and/or length below -2 Standard Deviations, who failed to show catch-up growth (height velocity SDS < 0 during the last year) by 4 years of age or later.

Treatment should be initiated and monitored by a paediatrician with expertise in managing childhood growth disorders and growth hormone therapy.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the New Drugs Committee and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 05 December 2005.

**Chairman,
Scottish Medicines Consortium**